Sophie Roux

Prix et distinctions

• (2023) Clinical Research Scholars. Université de Sherbrooke. (Prize / Award).
• (2023) Dean’s Recognition Award. Université de Sherbrooke. (Prize / Award).
• (2020) Dean's Recognition Award. Université de Sherbrooke. (Distinction).
• (2019) Clinical Research Scholars. Université de Sherbrooke. (Distinction).
• (2019) Dean's Recognition Award. Université de Sherbrooke. (Distinction).
• (2018) Dean’s Recognition Award. Université de Sherbrooke. (Prize / Award).
• (2017) Dean’s Recognition Award. Université de Sherbrooke. (Prize / Award).
• (2016) Dean’s Recognition Award. Université de Sherbrooke. (Prize / Award).
• (2015) Clinical Research Scholars – Senior. Fonds de recherche du Québec - Santé (FRQS). (Distinction).
• (2014) G. Plante's Career honorific award presentation. Université de Sherbrooke. (Distinction).
• (2011) Clinical Research Scholars – Junior 2. Fonds de recherche du Québec - Santé (FRQS). (Distinction).
• (2007) Clinical Research Scholars - Junior 1. Fonds de recherche du Québec - Santé (FRQS). (Distinction).
• Basic research award- Procter & Gamble. Société Française de Rhumatologie. (Prize / Award).

Financement

• Grant. (Under Review). Principal Applicant. New mediators and pathways in osteoclast biology. Natural Sciences and Engineering Research Council of Canada (NSERC). Discovery Grants program. 150 000 $. (2023-2028)
• Grant. (Awarded). Principal Investigator. Osteomorphs as biomarkers of osteoclast endophenotype and erosions in rheumatoid arthritis: a pilot project. Arthritis Society (The). Innovation Grant. 100 000 $. (2023-2025)
• Grant. (Awarded). Co-applicant. Deep-immune cell phenotyping by spectral flow cytometry to advance inflammatory arthritis and TNBC therapies. Canada Foundation for Innovation (CFI). John R. Evans Leaders Fund-John R. Evans Leaders Fund – Funding for research infrastructure. 1 200 000 $. (2023-2024)
• Grant. (Awarded). Co-applicant. NAS “Network-Attached Storage”. Centre de Recherche du Centre Hospitalier de l'Université de Sherbrooke Inc. (CRCHUS) (Sherbrooke, QC). Internal funding - small research equipment. 6 424 $. (2023-2024)
• Grant. (Awarded). Co-investigator. Mass spectrometry derived proteomic as a biomarker of rheumatoid arthritis outcomes and risk of cancer development. Centre de Recherche du Centre Hospitalier de l'Université de Sherbrooke Inc. (CRCHUS) (Sherbrooke, QC). Institutional Structural project grant. 75 000 $. (2022-2023)
• Grant. (Completed). Co-applicant. Investigating the potential of acoustic waves on implantable devices for controlled healing and biofilm prevention. Centre de Recherche du Centre Hospitalier de l'Université de Sherbrooke Inc. (CRCHUS) (Sherbrooke, QC). PAFI - Programme d’aide de financement interne. 25 000 $. (2022-2023)
• Grant. (Completed). Co-applicant. Study of the impact of IL-15 on human osteoclasts. Centre de Recherche du Centre Hospitalier de l'Université de Sherbrooke Inc. (CRCHUS) (Sherbrooke, QC). Programme d'aide financière interne (PAFI). 25 000 $. (2022-2023)
• Grant. (Completed). Principal Applicant. New mediators of osteoclast biology. Natural Sciences and Engineering Research Council of Canada (NSERC). Discovery Grants Program - Individual. 186 000 $. (2016-2022)
• Grant. (Completed). Co-applicant. Clinicopatholgical correlates of long COVID and potential interventions for improving the quality of life. Canadian Institutes of Health Research (CIHR). Emerging COVID-19 Research Gaps and Priorities Funding Opportunity (March 2021) - Post COVID-19 cond. 490 000 $. (2021-2022)
• Grant. (Completed). Principal Applicant. Identification of dominant SARS-CoV-2 antigens in infected individuals. Canadian Institutes of Health Research (CIHR). SARS-CoV-2 variants supplement: COVID-19 Rapid Research Funding Opportunity – Stream 1.. 50 000 $. (2021-2022)
• Grant. (Completed). Co-applicant. Refining biomarkers for erosive risk in rheumatic arthritis in order to tailor anti-rheumatic therapies. Centre de Recherche du Centre Hospitalier de l'Université de Sherbrooke Inc. (CRCHUS) (Sherbrooke, QC). Programme d'aide financière interne (PAFI). 25 000 $. (2020-2022)
• Grant. (Completed). Principal Investigator. Early prediction of bone erosiveness in rheumatoid arthritis using miRNAs. Canadian Institutes of Health Research (CIHR). Project Grant Program. 611 600 $. (2016-2021)
• Grant. (Completed). Principal Applicant. Characterization of Covid-19 infection in rheumatoid arthritis patients. Canadian Institutes of Health Research (CIHR). Rapid Research Funding Opportunity competition. 502 000 $. (2020-2021)
• Grant. (Completed). Co-applicant. Liquid handler acquisition for high throughput protocols. Centre de Recherche du Centre Hospitalier de l'Université de Sherbrooke (CRCHUS). Concours Petits équipements de recherche du CRCHUS (PERC). 20 000 $. (2020-2021)
• Grant. (Completed). Principal Applicant. Contribution to the constitution of the rheumatology biobank to understand the essence of research for the good of the patient.. Arthritis Society (The). Arthritis Centre Grant Application. 15 000 $. (2019-2020)
• Grant. (Completed). Principal Investigator. Micro-RNA signature in osteoclasts and joint damage progression in rheumatoid arthritis. Pfizer Canada Inc.. Investigator Initiated Research (IIR) grant. 32 500 $. (2015-2016)
• Grant. (Completed). Co-investigator. Osteoporosis and Peripheral fractures: Treatment and Investigation using a Multidisciplinary approach at the chUS (OPTIMUS). Servier Canada Inc. The Alliance for Better Bone Health. Unrestricted grant program. 15 000 $. (2007-2016)
• Grant. (Completed). Principal Investigator. Specialist nurses in managing rheumatoid arthritis patients. Bristol-Myers Squibb Canada Inc.. BMS Canada Medical Grant. 10 000 $. (2015-2016)

Publications

Articles de revue

• *Nguyen HD, Lortie A, *Mbous Nguimbus L, *Marrugo J, Allard-Chamard H, Bouchard L, Boire G, Scott MS, Roux S. (2023). Osteoclast microRNA profiling to capture the erosive factor in rheumatoid arthritis. J Bone Miner Res Plus - (-), -. (In Press).
• Gaboury I, Dobkin P, Gendron F, Roberge P, Beaulieu MC, Gervais F, Dagenais P, Roux S, Boire G. (2022). Mindfulness-Based Stress Reduction to Improve Depression, Pain and High Patient Global Assessment in Controlled Rheumatoid Arthritis. Rheumatol Adv Pract 6 (3), 1. (Published).
• Kwakkenbos L, Ostbo N, Carrier ME, Nielson WR, Fedoruk C, Levis B, et al. (2022). Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program. Pilot Feasibility Stud (BMC) 8 (1), 45. (Published).
• *Roy M, *Stephens E, *Bouhour S, Roux S. (2021). Eur J Cell Biol 100 (3), 151145. (Published).
• Wu Y, Kwakkenbos L, Henry RS et al. and the SPIN Investigators. (2021). Factors associated with fears due to COVID-19: A Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 cohort study. J Psychosom Res 140 110314. (Published).
• Klionsky DJ, et al. (2021). Guidelines for the Use and Interpretation of Assays for Monitoring Autophagy (4th edition). Autophagy 17 (1), 1-382. (Published).
• Lee Y, Fox RS, Kwakkenbos L, et al. (2021). Pain levels and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a multicentre cross-sectional study. Lancet Rheumatol 3 (12), e844-e854. (Published).
• Roux, S. (2021). [Bone and joints in hematological malignancies (Myeloma excluded)]. Encycl Méd Chir (Elsevier, Paris), Rhumatologie-Orthopédie 2021 14-027-A-20. (Published).
• *Nguyen HD, Bisson M, Scott MS, Boire G, Bouchard L, Roux S. (2021). miR profile in pagetic osteoclasts: from large-scale sequencing to gene expression study. J Mol Med 99 (12), 1771-1781. DOI. (Published).
• Thombs B, Kwakkenbos L, Henri RS et al. (2020). Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. J Psychosom Res 139 110262. (Published).
• Carrier N, de Brum-Fernandes A, Liang P, Masetto A, Roux S, Biln NK, Maksymowych WP, Boire G. (2020). Impending Radiographic Erosive Progression Over the Following Year in a Cohort of Consecutive Patients with Inflammatory Polyarthritis: Prediction by Serum Biomarkers. RMD Open 6 e001191. (Published).
• *Jann J, *Gascon S, Roux S, Faucheux N. (2020). Influence of the TGF-beta Superfamily on Osteoclasts/Osteoblasts Balance in Physiological and Pathological Bone Conditions. Int J Mol Sci 21 (20), 7597. (Published).
• Gaboury I, Dobkin P, Roberge P, Beaulieu M-C, Dagenais P, Gervais F, Roux S, Boire G. (2020). Mindfulness-based reduction stress reduction for patients with rheumatoid arthritis and depressive symptoms: a pilot trial. International Journal of Whole Person Care 7 (1), 6-7. (Published).
• *Allard-Chamard H, Duford P, M. Durant M, de Brum-Fernandes AJ, Boire G, Komarova SV, Dixon SJ, Sims SM, Harrison R, Manolson MF, Roux S. (2020). Osteoclasts and their circulating precursors in Rheumatoid Arthritis: Relationships with disease activity and bone erosions. Bone Rep 12 100282. (Published).
• *Stephens E, *Roy M, Bisson M, *Nguyen HD, Scott MS, Boire G, Bouchard L, Roux S. (2020). Osteoclast signaling-targeting miR-146a-3p and miR-155-5p are downregulated in Paget’s disease of bone. Biochim Biophys Acta- Molecular Basis of Disease 1866 (10), n/a. (Published).
• Fortune, C. Gietzen, A. Guillot, G. et al. (2020). Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the SPIN-CHAT program to reduce anxiety among at-risk scleroderma patients. J Psychosom Res 135 110132. (Published).
• *Roy M, Roux S. (2020). Rab GTPases in Autophagy and Osteoclastic Bone Resorption. Int J Med Sci 20 (21), 7655. (Published).
• Roux S, Massicotte M-H, *Huot Daneault A, Brazeau-Lamontagne L, Dufresne J. (2019). Acute hypercalcemia and excessive bone resorption following anti-RANKL withdrawal: Case report and brief literature review. Bone 120 482-486. (Published).
• Kwakkenbos L, Cumin J, Carrier ME, Bartlett SJ, Malcarne VL, Mouthon L, Nielson WR, Rannou F, Welling J, Thombs BD, and the SPIN Investigators. (2019). Factors associated with patient-reported likelihood of using online self-care interventions: a Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. BMJ Open 9 (10), e029542. (Published).
• Harel D, Mills SD, Kwakkenbos L, Carrier ME, Nielsen K, Portales A, Bartlett SJ, Malcarne VL, Thombs BD; SPIN Investigators. (2019). Shortening patient-reported outcome measures through optimal test assembly: application to the Social Appearance Anxiety Scale in the Scleroderma Patient-centered Intervention Network Cohort. BMJ Open 9 (2), e024010. (Published).
• *Roy, M Roux, S. (2018). Rab GTPases in osteoclastic endomembrane systems. BioMed Research International Article ID 4541538 1-15. (Published).
• Roux, S. Cabana, F. Carrier, N. Beaulieu, M. C. Boire, G. (2018). Risk of Subsequent Fragility Fractures Observed After Low-Trauma Ankle Fractures. Calcif Tissue Int 103 (1), 62-70. DOI. (Published).
• Roux, S Gaboury, I *Gionet-Landry, N Garant, M-P Beaulieu, M-C Carrier, N Cabana, F Boire, G. (2018). Using a Sequential Explanatory Mixed Method to Evaluate the Therapeutic Window of Opportunity For Initiating Osteoporosis Treatment Following Fragility Fractures. Osteop Int 29 (4), 961-971. (Published).
• Mills SD, Kwakkenbos L et al. and the SPIN Investigators. (2018). Validation of the Social Appearance Anxiety Scale in Patients with Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study. Arthritis Care Res 70 (10), 1557-6. (Published).
• Roux, S. (2017). [Myeloma Bone disease: Pathophysiology]. Joint Bone Spine- Revue du Rhumatisme (Monographie) 84 181-186. (Published).
• *McManus S, Bisson M, *Chamberland R, *Roy M, *Nazari S, Roux S. (2016). Autophagy and Phospho-Inositide Dependent Kinase 1 (PDK1) -Related Kinome in Pagetic Osteoclasts. J Bone Miner Res 31 (7), 1334-1343. DOI. (Published).
• Beauvais S, Drevelle O, Jann J, Lauzon M-A, Foruzanmehr M, Grenier G, Roux S, Faucheux N. (2016). Interactions between bone cells and biomaterials: An Update. Frontiers in Bioscience 8 (Jun 1), 227-263. (Published).
• Roux S. (2015). [Bone and joints in hematological malignancies (Myeloma excluded)]. Encyclopédie Médico-Chirurgicale (EMC Rhumatologie-Orthopédie) 10 (1), 1-9. (Published).
• Roux S. (2015). [New advances in multiple myeloma bone disease and therapeutic applications]. Reflexions Rhumatologiques 19 (178), 7-11. (Published).
• Klinck R, Laberge G, Bisson M, *McManus S, Michou L, Brown JP, Roux S. (2014). Alternative splicing in osteoclasts and Paget’s disease of bone. BMC- Medical Genetics 15 (1), 98. (Published).
• Roux S, Cabana F, Carrier N, Beaulieu M, *April PM, Beaulieu M, Boire G. (2014). The World Health Organisation Fracture Risk Assessment tool (FRAX® without BMD) underestimates incident and recurrent fractures in consecutive patients with fragility fractures. J Clin Endocrinol Metab 99 (7), 2400-8. (Published).
• Bissonnette L , April PM , Dumais R , Boire G , Roux S. (2013). Atypical fracture of the tibial diaphysis associated with bisphosphonate therapy: A case report. Bone 56 (2), 406-9. (Published).
• *Fong D , Bisson M , Laberge G , *McManus S , Grenier G , Faucheux N , Roux S. (2013). Bone morphogenetic protein-9 activates Smad and ERK pathways and supports human osteoclast function and survival in vitro. Cellular Signalling 25 (4), 717-728. (Published).
• *Chamoux E , *McManus S , Laberge G , Bisson M , Roux S. (2013). Involvement of kinase PKC-zeta in the p62/p62(P392L)-driven activation of NF-kappaB in human osteoclasts. Biochimica Biophysica Acta - Molecular Basis of Disease 1832 (3), 475-84. (Published).
• Roux S, Beaulieu M, Beaulieu MC, Cabana F, Boire G. (2013). Priming Primary Care Physicians to Treat Osteoporosis After a Fragility Fracture: An Integrated Multidisciplinary Approach. J Rheumatol 40 (5), 703-11. (Published).
• *McManus S , Chamoux E , Bisson M , Roux S. (2012). Modulation of tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors in a human osteoclast model in vitro. Apoptosis 17 (2), 121-31. (Published).
• Yue L, Durand M , Lebeau Jacob MC , Hogan P , *McManus S , Roux S , de Brum-Fernandes AJ. (2012). Prostaglandin D(2) induces apoptosis of human osteoclasts by activating the CRTH2 receptor and the intrinsic apoptosis pathway. Bone 51 (3), 338-346. (Published).
• *McManus S, Roux S. (2012). The adaptor protein p62/SQSTM1 in osteoclast signaling pathways. J Mol Signal 7 (1), 1. (Published).
• Trensz F , Haroun S , Drouin G , Bergeron E , Penton CM , Montanaro F , Roux S , Faucheux N , Grenier G. (2011). BMP-9-induced muscle heterotopic ossification requires changes to the skeletal muscle microenvironment. J Bone Miner Res 26 (6), 1166-77. (Published).
• Roux S. (2011). [The RANK-RANKL-OPG axis in rheumatoid arthritis]. Reflexions Rhumatologiques 15 (143), 10-13. (Published).
• Roux S. (2011). [The RANKL-RANK pathway: an update]. Reflexions Rhumatologiques 15 (143), 4-9. (Published).
• Bergeron E , Senta H , Lauzon MA , Roux S , Grenier G , Faucheux N. (2010). Effect of functionalized polycaprolactone on the behaviour of murine preosteoblasts. Biomaterials 31 (25), 6468-76. (Published).
• Michou L, *Chamoux E , *Couture J , Morissette J , Brown JP , Roux S. (2010). Gene expression profile in osteoclasts from patients with Paget's disease of bone. Bone 46 (3), 598-603. (Published).
• Gallant MA , *Chamoux E , Bisson M , Wolsen C , Parent JL , Roux S , de Brum-Fernandes AJ. (2010). Increased concentrations of prostaglandin D2 during post-fracture bone remodeling. J Rheumatol 37 (3), 644-9. (Published).
• Roux S. (2010). New treatment targets in osteoporosis. Joint Bone Spine 77 (3), 222-8. (Published).
• Roux S, Mariette X. (2010). RANK and RANKL expression in giant-cell tumour of bone (letter). Lancet Oncol 11 (6), 514. (Published).
• *Chamoux E, Bisson M , Payet MD , Roux S. (2010). TRPV-5 mediates a receptor activator of NF-kappaB (RANK) ligand-induced increase in cytosolic Ca2+ in human osteoclasts and down-regulates bone resorption. J Biol Chem 285 (33), 25354-62. (Published).

Numéros de revue

• Roux S, et al. (2020). New insights in osteoclasts’ biology. International of Molecular Sciences (Published).

Chapitres de livre

• Confavreux CB, Massy E, Tingry T, Follet H, Roux S. (2020). Malignant Bone Diseases and Rheumatic immune adverse events related to immune checkpoint inhibitors. EULAR Textbook on Rheumatic Diseases (4th Edition, since 2009, 86 pages). United Kingdom : BMJ Edition. (Published).
• Allard-Chamard, H. Debiais, F. Roux, S. (2018). Malignant Bone Diseases (as they apply to rheumatic diseases). J.W.J. Bijlsma, E. Hachulla (Eds.), J. Da Silva, F. Buttgereit, M.A. Cimmino, F. Lioté, & T. O’Neill (Co-Eds.).. EULAR Textbook on Rheumatic Diseases (3rd Edition, Chap 34). United Kingdom : BMJ. (Published).
• Roux S, Philippin G, Vieillard MH. (2012). Malignant Bone Diseases. J.W.J. Bijlsma (Ed.), J. Da Silva, E. Hachulla, M. Doherty, A. Cope & F. Lioté (Co-Eds.). Textbook on Rheumatic Diseases (p 808-833). United Kingdom : BMJ Editions. (Published).
• *McManus, S *Bissonette, L Roux, S. (2012). Osteoclast biology in Paget's disease of bone. Brown, A. J. Walker, J. S.. Osteoclasts: Morphology, Functions and Clinical Implications (NOVA Science Publishers, p 77-94). United States of America : Nova Science Publishers. (Published).

Articles de journaux

• (2007). Those too brittle bones. The Record. 12.

Rapports

• Roux Sophie. (2022). Meeting Report: ASBMR 2022. Novartis. 10 p.
• Roux Sophie. (2020). Meeting Report: ASBMR 2019. Amgen. 20 p.
• Roux Sophie. (2019). Meeting report: ASBMR 2018. Amgen. 20 p.
• Roux S. (2018). Meeting Report: ASBMR 2017. Amgen. 20 p.
• Roux, S. (2016). Meeting Report: ASBMR 2015. Eli Lilly Canada and AMGEN Canada Inc.. 10 p.
• Roux, S. (2014). Meeting Report: ASBMR 2014. Eli Lilly Canada Inc..
• Roux, S. (2013). Meeting Report: ASBMR 2013. AMGEN Canada INC..
• Roux S. (2012). ASBMR 2012, Minneapolis. www.rhumato.net. 20 p.
• Roux S. (2011). ASBMR 2011, San Diego. www.rhumato.net. 20 p.
• Roux S. (2010). ASBMR 2010, Toronto. www.rhumato.net. 20 p.

Manuels

• Roux S. (2023). [Hyperparathyroidism]. GRIO (Groupe de Recherche et d'information sur les ostéoporoses). (Bone Diseases, Since 2009). 11 p. (Published).
• Roux S. (2023). [Physiopathology of myeloma bone disease]. (Inter-university course, Since 2013). 14 p. (Published).
• Roux S, Massy E, Confavreux CB. (2020). Joint involvement in AL amyloidosis. In-depth discussion. (EULAR Online courses on Rheumatic Diseases, Since 2009). 4 p. (Published).
• Confavreux CB, Massy E, Tingry T, Follet H, Roux S. (2020). Malignant Bone Diseases (as they apply to Rheumatic Diseases). Module 41c. BMJ Editions. (EULAR Online courses on Rheumatic Diseases, Since 2009). 89 p. (Published).
• Confavreux C, Roux S. (2020). Medication-Related osteonecrosis of the jaw. In-depth discussion. BMJ Group. (EULAR Online courses on Rheumatic Diseases). 12 p. (Published).
• Tingry T, Massy E, Roux S, Confavreux CB. (2020). Rheumatic immune adverse events related to immune checkpoint inhibitors (IrAEs related to ICI). In-depth discussion. BMJ Group. (EULAR Online courses on Rheumatic Diseases). 17 p. (Published).

Lignes directrices en matière de soins cliniques

• S. Roux, G. Boire, F. Cabana. (2011). Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis (OPTIMUS).

Articles de conférence

• Boire G, Carrier N, Roux S, Allard-Chamard H. (2023). Cardiovascular and Thromboembolic Events in Rheumatoid Arthritis and Psoriatic Arthritis Over 3 Years Before and 3 Years After Initiation of a First Advanced Therapy. Data from the University of Sherbrooke Registry of Advanced Therapies (USRAT). EULAR (European Alliance of Associations for Rheumatology) European Congress of Rheumatology. (Accepted).
• *Couture AA, Carrier N, Roux S, Allard-Chamard H, Liang P, Boire G. (2023). Discordance in Patient and Evaluator Global Assessment of Disease Activity Over Time and Across Disease Activity Levels in Recent-Onset Rheumatoid Arthritis. EULAR. (Accepted).
• *Mbous Nguimbus L, *Roy M, Brunet MA, Roux S. (2023). Interactome of Galectin-8 Isoforms to Dissect their Impact on Human Osteoclasts. ASBMR (American Society for Bone and Mineral Research). (Submitted).
• *Goguen-Couture V, *Badiane PY, *Roy M, Brosseau J-P, Roux S. (2023). Ubiquitin Specific Peptidase 4 (USP4) and isoforms in osteoclast biology. ASBMR (American Society for Bone and Mineral Research). (Submitted).
• Carrier N, Roux S, Allard-Chamard H, Boire G. (2022). Cardiovascular and Thromboembolic Events in Rheumatoid Arthritis Patients Before and After Initiation of a First Advanced Therapy. ACR/ARHP Annual Meeting. (Published).
• *Vencic J, Roux S, Scott M, Allard-Chamard H. (2022). Defining immune cells expression profiles with single-cell RNAseq in Rheumatoid Arthritis patients naive to treatment. ISMB 2022 (Intelligent Systems for Molecular Biology 2022). (Published).
• *Vencic J, Roux S, Scott M, Allard-Chamard H. (2022). Investigation of the immune endophenotypes of Rheumatoid Arthritis with single-cell RNAseq analysis of patient’s PBMC. CRA (Canadian Rheumatology Association) annual meeting, Feb 2022 (online meeting). (Published).
• Gaboury I, Dobkin P, Beaulieu MC, Gervais F, Gendron F, Roberge P, Dagenais P, Roux S, Boire G. (2022). Mindfulness-Based Stress Reduction (MBSR) in Rheumatoid Arthritis(RA) Patients: a Patient-Related Outcome (PRO)-Based Pilot Trial. CRA (Canadian Rheumatology Association) annual meeting. (Published).
• *Nguyen HD, Lortie A, Bouchard L, Allard-Chamard H, Boire G, Scott MS, Roux S. (2022). Osteoclast miRNA and target gene expression profiles in machine learning-based prediction of bone erosions in Rheumatoid Arthritis. ASBMR (American Society for Bone and Mineral Research) (online meeting). (Published).
• *Mbous Nguimbus L, *Roy M, Scott M, Brunet M, Roux S. (2022). Proteomic analysis of the galectin-8 isoform interactome. Journée PHARE, Congrès québécois en sciences de la santé. (Published).
• Limoges MA, Roux S, Boire G, Allard-Chamard H, Piché A, Ramanathan S. (2022). T and B cell responses to SARS-Co-V-2 mRNA vaccines in immunocompromised rheumatoid arthritis patients (oral communication). 9th Annual symposium on Cytokines in Inflammation, Ageing, Cancer and Obesity (CIACCO). (Published).
• Akman, Z Boire, G Carrier, N Roux, S Masetto, A de Brum-Fernandes, AJ Liang, P Dobkin, PL Allard-Chamard, H. (2021). Coping with recent-onset Rheumatoid Arthritis (RA): Validation of the Coping with Health Injuries and Problems (CHIP) questionnaire in a longitudinal cohort. ACR/ARHP Annual Meeting (Online). (Accepted).
• Gaboury I, Dobkin P, Roberge P, Beaulieu MC, Dagenais P, Gervais F, Roux S, Boire G. (2021). Mindfulness-Based Stress Reduction (MBSR) to Improve Patient-Related Outcomes (PROs) in Patients with Rheumatoid Arthritis in Clinical Remission but Elevated Negative PROs: A Pragmatic Pilot Study. ACR/ARHP Annual Meeting (Online). (Accepted).
• Carrier N, Roux S, Masetto A, Fernandes A, Liang P, Maoui M, Boire G. (2021). Observations on Biomarkers in Very Early Rheumatoid Arthritis Over 20 Years, from Baseline Presentation to Five-Year Outcomes. CRA (Canadian Rheumatology Association) annual meeting, Feb 2021 (online meeting). (Published).
• *Roy M, *Stephens E, *Bouhour S, Roux S,. (2020). American Society for Bone and Mineral Research. (Published).
• Beaulieu MC, Gaboury I, Carrier N, Dobkin P, Gervais F, Gendron F, Roberge P, Dagenais P, Roux S, Boire G. (2020). Mindfulness-Based Stress Reduction to Improve Depressive Symptoms and Rheumatoid Arthritis-Related Clinical Outcomes: Results from a Feasibility and Acceptability Trial. EULAR Frankfurt, Germany June 2020. (Accepted).
• Gaboury I, Dobkin P, Roberge P, Beaulieu MC, Dagenais P, Gervais F, Roux S, Boire G. (2020). Mindfulness-Based Stress Reduction to Improve Depressive Symptoms and Rheumatoid Arthritis-Related Clinical Outcomes: Results from a Feasibility and Acceptability Trial. CRA (Canadian Rheumatology Association) annual meeting, Victoria Feb, 2020. (Published).
• Carrier N, Roux S, Masetto A, deBrum Fernandes A, Liang P, Maoui M, Boire G. (2020). Outcomes over the first 5 years of follow up in a very early rheumatoid arthritis (RA) cohort recruited over 20 years: most of the improvement occured before the 2011 implementation of treat-to-target. EULAR Frankfurt, Germany June 2020. (Accepted).
• *Stephens E, Bisson M, *Roy M, Roux S. (2019). . MicroRNA146a in human osteoclasts and Paget’s disease of Bone. ASBMR (American Society for Bone and Mineral Research) Orlando Sept 2019. United States of America, (Published).
• *Stephens E, Bisson M, *Roy M, Roux S. (2019). Dysregulated microRNA expression in osteoclasts from Paget’s Disease of Bone. CCTC (Canadian Connective Tissue Conference) annual meeting. Canada, (Published).
• *Allard-Chamard H, Carrier N, de Brum-Fernandes AJ, Boire G, Komarova SV, Harrison R, Manolson MF, Roux S. (2019). In Vitro Osteoclast Differentiation in ArthritisOsteoclast Precursor Assessment In Rheumatoid Arthritis: The (IODA) study. ASBMR (American Society for Bone and Mineral Research) Orlando Sept 2019. United States of America, (Published).
• *Stephens E, Bisson M, *Roy M, Roux S. (2019). MicroRNA profile in osteoclasts from Rheumatoid arthritis and Paget’s Disease of Bone. Osteoclast Mini Symposium, Montreal May 2019. Canada, (Published).
• Gaboury I, Dobkin P, Roberge P, Beaulieu MC, Dagenais P, Gervais F, Roux S, Boire G. (2019). Mindfulness-Based Stress Reduction (MBSR) for patients with rheumatoid arthritis and depressive symptoms: a pilot trial. 3rd International Congress on Whole Person Care. Montreal Oct 2019. Canada, (Accepted).
• Carrier N, Roux S, Masetto A, deBrum Fernandes A, Liang P, Maoui M, Boire G. (2019). Outcomes over the first 5 years of follow up in a very early rheumatoid arthritis (RA) cohort recruited over 20 years: most of the improvement occured before the 2011 implementation of treat-to-target. ACR/ARHP Annual Meeting, Atlanta - Nov 2019. United States of America, (Accepted).
• Carrier N, Roux S, Masetto A, deBrum Fernandes A, Liang P, Maoui M, Boire G. (2019). The Changing Faces of Rheumatoid Arthritis Patients at Presentation: A 20-Year Study. CRA (Canadian Rheumatology Association) annual meeting, Montreal Feb, 2019. Canada, (Published).
• Boire G, Dobkin P, Gaboury I, Gervais F, Beaulieu MC, Dagenais P, Roberge P, Roux S. (2018). Adressing Persistent DepressiveSymptoms in Rheumatoid Arthritis Patients with Controlled Disease. CRA (Canadian Rheumatology Association) annual meeting, Vancouver 2018. (Accepted).
• Boire G, Carrier N, deBrum Fernandes AJ, Liang P, Masetto A, Roux S, Biln NK, Gui Y, Savill J, Michienzi S, Maksymowych WP. (2018). Levels of 14-3-3eta Protein Are an Independent Predictor of Radiographic Progression in Patients with Inflammatory Polyarthritis. ACR/ARHP Annual Meeting, Chicago 2018. (Accepted).
• *Roy M, Bisson M, Roux S. (2018). TBC1D25 in human osteoclasts: impact on autophagy and bone resorption. CCTC (Canadian Connective Tissue Conference) annual meeting- Toronto 2018. (Published).
• Carrier N, Roux S, Masetto A, deBrum Fernandes A, Liang P, Maoui M, Boire G. (2018). The Changing Faces of Rheumatoid Arthritis Patients at Presentation: A 20-Year Study. ACR/ARHP Annual Meeting, Chicago 2018. (Accepted).
• *Roy M, Bisson M, Roux S. (2017). Expression and function of TBC1D25 in human osteoclasts. J Bone Miner Res, (Published).
• *Allard-Chamard Hugues, Boire Gilles, De Brum -Fernandes Artur, Scott Michelle, Bouchard Luigi, and Roux Sophie. (2016). Osteoclast microRNA profiling in erosive rheumatoid arthritis. American Society for Bone and Mineral Research- Annual meeting. (Published).
• *McManus S, Bisson M, *Chamberland R, *Roy M, *Nazari S, Roux S. (2015). Autophagy and Phospho-Inositide Dependent Kinase 1 (PDK1) -Related Kinome in Pagetic Osteoclasts. J Bone Miner Res 2015, (Published).
• Rodrigue L, Cabana F, Carrier N, Sale J, Roux S, Boire G. (2015). Characteristics of Patients Classified as Low or Moderate Risk Based on Fracture Risk Assessment (FRAX) After a Fragility Fracture. J Bone Miner Res 2015, (Published).
• April PM, Boire G, Cabana F, Beaulieu MC, Roux S. (2015). Up to half of first Fragility Fractures (FF), and a third of recurrent FF, occurin patients with low or moderate estimated FRAX® 10-year fracture risk: resultsfrom the OPTIMUS initiative. 3rd World Congress on Controversies, Debate & Consensus in Bone, Muscle & Joint Diseases (BMJD). (Published).
• Gionet-Landry N, Cabana F, Gaboury I, Boire G, Roux S, Carrier N, Beaulieu MC. (2015). Why patients still untreated 1 year after a Fragility Fracture refuse an intervention to treat osteoporosis?. J Bone Miner Res 2015, (Published).
• Cabana F, Beaulieu MC, Carrier N, Roux S, Boire G. (2014). How long does the therapeutic window ofopportunity last after a fragility fracture?. J Bone Miner Res, (Published).
• Beaulieu MC, Cabana F, Beaulieu M, Carrier N, Roux S, Boire G. (2014). Improving treatment adherence through rapid integrated interdisciplinary intervention after a fragility fracture: the OPTIMUS initiative. Canadian Rheumatology Association (CRA). (Accepted).
• Cabana F, Péladeau M, Carrier N, Beaulieu MC, Beaulieu M, Roux S, Boire G. (2014). Which patients with low trauma ankle fractures are at risk for subsequent fragility fractures in the Optimus cohort?. Canadian Rheumatology Association (CRA). (Accepted).
• Beaulieu MC, Cabana F, Beaulieu M, Carrier N, Roux S, Boire G. (2013). Improving Adherence Through Rapid Integrated Interdisciplinary Intervention After A Fragility Fracture. NAPCRG 41st Annual Meeting. (Published).
• *McManus S, Laberge G, Bisson M, Roux S. (2013). PDK1/Akt pathway is involved in osteoclast signaling in Paget’s disease of bone. J Bone Miner Res 2013, 29 (suppl 1), S273. (Published).
• April PM, Cabana F, Beaulieu MC, Beaulieu M, Roux S, Boire G. (2013). Up to half of first fragility fractures (FF), and a third of recurrent FF, occur in patients with low or moderate estimated FRAX® 10-year fracture risk: results from the OPTIMUS initiative. Ann Rheum Dis 2013; 72 (suppl 2), (Published).
• Cabana F, Carrier N, Beaulieu MC, Beaulieu M, Roux S, Boire G. (2013). Which Patients with Ankle Fractures Are at Risk for Recurrent Fragility Fractures? Results from the OPTIMUS Initiative. J Bone Miner Res 2013, 29 (suppl 1), S436. (Published).
• April PM, Poirier N, Roux S, Beaulieu MC, Beaulieu M, Cabana F, Boire G. (2012). Estimated Frax® 10-Year Fracture Risk at the Time of Incident Fracture and Upon Refracture: Results from the OPTIMUS Initiative. J Bone Miner Res 2012, 27 (suppl 1), S115. (Published).
• Cabana F, Roux S, Beaulieu MC, Beaulieu M, Boire G. (2012). Incidence of subsequent fractures according to site of initial non-vertebral fractures and treatment status (OPTIMUS). Ann Rheum Dis 2012; 71 (suppl 3), 589. (Published).
• Beaulieu MC, Roux S, Poirier N, Beaulieu M, Cabana F, Boire G. (2012). Management of fragility fractures: impact of the OPTIMUS initiative on family physicians. J Bone Miner Res 2012, 27 (suppl 1), S109. (Published).
• Beaulieu MC, Cabana F, Beaulieu M, Roux S, Boire G. (2012). Management of fragility fractures: impact of the OPTIMUS initiative on family physicians. 1st FFN (Fracture Fragility Network) Global Congress. (Published).
• Beaulieu MC, Cabana F, Beaulieu M, Roux S, Boire G. (2012). Management of fragility fractures: impact of the optimus initiative on family physicians. Ann Rheum Dis 2012; 71 (suppl 3), 596. (Published).
• de Brum-Fernandes AJ, Yue L, Roux S, *McManus S. (2012). Prostaglandin D2 Induces Apoptosis of Human Osteoclasts Through the Activation of Akt and ERK Signaling Pathways. J Bone Miner Res 2012, 27 (suppl 1), S414. (Published).
• *Boulay-Jean S, *McManus S, Roux S. (2012). [Role of the p62P392L mutation in the activation of NFATc1 in paretic osteoclasts]. Scientific meeting FMSS, 41st Edition, Sherbrooke University. (Published).
• Cabana F, Beaulieu M, Lambert D, Cote P, Vaillancourt M, Beaulieu M, Roux S, Boire G. (2011). Incidence of Subsequent Fractures According to Age and Site of Initial Non-Vertebral Fractures (OPTIMUS). J Bone Miner Res 2011; 26 (suppl 1), S484. (Published).
• *Chamoux E, Bisson M, Brown J, Roux S. (2010). p62, PKCzeta and NF-kappaB Signaling in Human Osteoclasts: a Link With Paget's Disease of Bone. J Bone Miner Res 2010, 25 (suppl 1), S185. (Published).

Autres contributions

Cours enseignés

• Frequent or severe systemic inflammatory and hematological situations. MSP224. (2019-01-15 à 2020-10-13).
• clinical approach to musculoskeletal disorders of the lower limb. MSP124. (2018-03-26 à 2022-12-15).
• clinical approach to musculoskeletal disorders of the upper limb. MSP114. (2017-11-06 à 2022-12-16).
• Online Course : "Malignant Bone Diseases (as they apply to Rheumatic Diseases)". EULAR Online. (2017-09-01 à 2022-08-23).EULAR- The European League Against Rheumatism. Niveau : Post Graduate.
• Online Course: Rheumatology-Oncology. DIU. (2012-12-03 à 2022-02-15).Société Française de Rhumatologie. Niveau : Post Graduate.
• Online Course on Rheumatic Diseases. EULAR Online. (2007-10-17 à 2014-05-01).EULAR- The European League Against Rheumatism. Niveau : Post Graduate.
• Online Course: Medical bone diseases. DIU. (2006-04-03 à 2022-06-15).GRIO (Groupe de Recherche et d'Information sur les Ostéoporoses). Niveau : Post Graduate.
• Musculoskeletal Learning Unit. MDP161. (2003-04-08 à 2016-04-01).
• Molecular Endocriniology. BCM 606. (2003-01-01 à 2022-06-14).
• Clinical Immunology. IML 711. (2002-04-30 à 2022-06-14).

Présentations

• (2023). Osteoporosis: the latest advances. Bone symposium (June 2023). Sherbrooke
• (2023). [Osteoporosis - an overview for non-bone specialists]. Medical Grand Rounds (May 2023). Sherbrooke
• (2021). [Advances in osteoporosis management]. TOP3 Rheumatology (Association of Rheumatologists of Quebec / Association des medecins rhumatologues du Quebec (AMRQ) (virtual meeting). Sherbrooke, Canada
• (2021). [Osteoclast and Osteoimmunology in Rheumatoid arthritis]. 34th annual French Society Congress (Société Française de Rhumatologie) In-person meeting, Paris. Paris, France
• (2021). [Osteoporosis: not to be missed - an overview for healthcare professionals]. Interdisciplinary meeting of rheumatology (Federation of Medical Specialists of Quebec - FMSQ) (virtual meeting). Virtual meeting, Canada
• (2020). Hot Topics on Bone Diseases (Workshop). CRA annual meeting (Canadian Rheumatology Association) In-person meeting, Victoria (BC). Victoria (BC), Canada
• (2020). Osteoporosis management (meet-the-professor session). CRA annual meeting (Canadian Rheumatology Association) In-person meeting. Victoria (BC), Canada
• (2020). [ASBMR 2019 Annual Meeting highlights]. Bone symposium- Feb 2020 In-person meeting. Sherbrooke, Canada
• (2020). [New advances in Osteoporosis management: An update for general practioners]. Bone Symposium- November 2020. Sherbrooke, Canada
• (2019). ASBMR 2018 Annual Meeting highlights. Bone symposium- Feb 2019. Sherbrooke, Canada
• (2019). Romosozumab: a new anti-osteoporotic agent. Bone meeting- Nov 2019. Sherbrooke, Canada
• (2018). Advances in Osteoporosis Management. Geriatric department. Sherbrooke, Canada
• (2018). New insights in bone biology and bone diseases. Grand Round. Canada
• (2016). New therapeutic targets in osteoporosis: Sclerostin and beyond. Annual meeting: Association of Endocrinology in Quebec, Montréal. Montréal, Canada
• (2016). [Osteoporosis in the Elderly]. Journée conjointe de Rhumato-Gériatrie. Magog-Orford, Canada
• (2014). [Osteoclasts in bone diseases and rheumatoid arthritis]. Career honorific award presentation Annual scientific meeting FMSS. Sherbrooke, Canada
• (2014). [Oversuppression of bone turnover with anti-catabolic agents]. 45e Conférence laurentienne de rhumatologie. Mont-Tremblant, Canada
• (2013). p62-related signaling and autophagy in pagetic osteoclasts. Cell Biology Seminar, Toronto. Toronto, Canada
• (2012). [New targets in malignant osteolysis]. Francophones d’Oncologie Médicale. Lille, France